| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b892e632992bc369c922c70802ef565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8cfb31b2531409c6d60265a213f8365f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fe04afb7c7a85810ba9497d486fda6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d09f35425655fb2c47df80bc4b538b80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6c96136b645457a308123eb97cbc003 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cabf8b9021f70a7a651105c4d93790c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcf54a0042319afb2c94c1c7cb242881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60e638e4d7d5b468ac287cb4003f8c01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd35c48079781a70eff449823b6929b |
| publicationDate |
2012-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012053828-A2 |
| titleOfInvention |
Human interleukin-1 receptor antagonist - hybrid fc fusion protein |
| abstract |
The present invention relates to a fusion protein resulting from the coupling of a human interleukin-1 receptor antagonist and hybrid Fc. More specifically, provided is a fusion protein in which a human interleukin-1 receptor antagonist is coupled to a human immunoglobulin (Ig) hybrid Fc fragment. The hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the fusion protein. The pharmaceutical composition of the present invention can be used for the treatment of autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease (e.g. Crohn's disease and ulcerative bowel disease), psoriasis, diabetes and the like. The fusion protein of the present invention can be expected to be usable in the development of new autoimmune-disease drugs which maintain far better efficacy and have fewer side effects than existing autoimmune-disease drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022010319-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3998279-A4 |
| priorityDate |
2010-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |